Authors
Lyvia Neves Rebello Alves Nolasco, Eldamária de Vargas Wolfgramm Dos Santos, Raquel Silva Dos Reis Trabach, Débora Dummer Meira, Iúri Drumond Louro
Published in
Biochimica et biophysica acta. General subjects. Pages 131009. Sep 24, 2026. Epub Sep 24, 2026.
Abstract
Rapamycin is a macrolide compound originally identified for its antifungal activity and subsequently recognized as a potent inhibitor of the mechanistic target of rapamycin (mTOR), a conserved signaling kinase that integrates nutrient availability, growth factor signals, and cellular stress responses to regulate cell growth and metabolism. This review examines rapamycin across biological and medical fields, covering its discovery, chemical and pharmacological properties, and the central role of mTOR as its primary molecular target. We summarize established and emerging clinical applications of rapamycin and its analogs, while critically addressing the limitations and adverse effects associated with mTOR inhibition. Furthermore, advances in translational research and future perspectives are also discussed. Collectively, current evidence supports mTOR inhibition as a unifying biological strategy for the prevention, treatment, and delayed onset of multiple chronic diseases, as well as for promoting healthspan. As the first clinically approved mTOR inhibitor, rapamycin has therefore become a foundational pharmacological tool for exploring the therapeutic potential of modulating the evolutionarily conserved mTOR signaling network across a broad spectrum of human diseases and age-related conditions.
PMID:
42785697
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0